Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Releases Q1 Economic Report On Pharmaceutical Industry

This article was originally published in PharmAsia News

Executive Summary

China's National Development and Reform Commission (NDRC) has released the Q1 2008 report on the economic progress of key industries. The economic profit of the pharmaceutical industry increased 18.6 percent compared to the same period last year. Chemical medicine output hit 783,000 tonnes while patented Chinese medicine reached 273,000 tonnes, with increases of 11.7 and 10.2 percent, respectively. In the first two months of this year, the pharmaceutical industry realized a profit of 9.41 billion yuan, 50.1 percent higher than the same period in 2007. NDRC forecasts that the growth in output and sales will continue to maintain a level of over 20 percent for this year. With the government's growing investment in health care and tighter industrial supervisory policies, observers are positive about the pharmaceutical industry's outlook. (Click here for more - Chinese Language)

You may also be interested in...

Genomma Enjoys Strong Q2 Thanks To Big Gains in US

Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation. 

Executives On The Move: New CEOs At Alentis Therapeutics, Melinta Therapeutics And NBE-Therapeutics

New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.

Cadila Pharma Launches Rituximab And Teriparatide Biosimilars In India

After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts